On March 27, 2019 Crown Bioscience, a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation and autoimmune, cardiovascular and metabolic disease research reported that parent company, JSR Corporation, has entered into a strategic partnership with Hubrecht Organoid Technology (HUB) (Press release, JSR, MAR 27, 2019, View Source [SID1234553813]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement provides CrownBio, a wholly owned subsidiary of JSR Corporation, with an exclusive license to provide preclinical oncology drug development and validation services using HUB Organoid Technology, including access to HUB’s highly characterized tumor organoid biobank. CrownBio and HUB will also launch a collaborative research & development program to accelerate further development of Organoid Technology, while CrownBio will establish a new operations center in Utrecht, Netherlands.
HUB’s adult stem cell-derived organoids, developed by Prof. Hans Clevers at the Hubrecht Institute in Utrecht, are generated using highly standardized, proprietary culture methods. The Organoids faithfully recapitulate tumors in patients and are extensively characterized by pathology, genomics, and sensitivity to known and experimental drugs.
"This agreement is a pivotal moment in our growth and the evolution of the company," said Dr. Jean-Pierre Wery, CEO of CrownBio. "This partnership positions CrownBio at the forefront of global preclinical research by creating an unparalleled translational platform to accelerate drug development and validation."
Building on a global leadership in Patient-Derived Xenografts (PDX), CrownBio will offer comprehensive pharmacology and translational services based on HUB Organoid Technology, establishing a unique platform that incorporates in vitro screening of Patient-Derived Organoids (PDO) and PDX derived organoids (PDXO), matched to downstream in vivo models.
"We are delighted with the increased access to HUB Organoid Technology for researchers worldwide through CrownBio’s global reach and preclinical service expertise," said Dr. Robert Vries, Executive Director of HUB. "Our partnership with CrownBio equips the drug development community with powerful new translational tools to guide the creation of novel and improved treatments for cancer."